Antisense 'knockdowns' of M1 receptors induces transient anterograde amnesia in mice

Neuropharmacology

Volumn 38, Issue 3, 1999, Pages 339-348

  Ghelardini, Carla ^a   Galeotti, Nicoletta ^a   Matucci, Rosanna ^a   Bellucci, Cristina ^a   Gualtieri, Fulvio ^a   Capaccioli, Sergio ^a   Quattrone, Alessandro ^a   Bartolini, Alessandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Amnesia; Antisense oligonucleotide; Central cholinergic system; Learning; M1 receptors; Memory

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; MUSCARINIC M1 RECEPTOR; DRUG DERIVATIVE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE; TELENZEPINE;

AMNESIA; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; HIPPOCAMPUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LEARNING; MALE; MEMORY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE AVOIDANCE; PRIORITY JOURNAL; ANIMAL; AVOIDANCE BEHAVIOR; BRAIN CORTEX; BRAIN VENTRICLE; CELL MEMBRANE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REACTION TIME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

AMNESIA; ANIMALS; AVOIDANCE LEARNING; CELL MEMBRANE; CEREBRAL CORTEX; CEREBRAL VENTRICLES; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; MEMORY; MICE; MUSCARINIC ANTAGONISTS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PIRENZEPINE; REACTION TIME; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 0032586761     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00194-4     Document Type: Article

References (52)

1. Bartus, R.T., Johnson, H.R., 1976. Short-term memory in the rhesus monkey: disruption from the anticholinergic scopolamine. Pharmacol. Biochem. Behav. 5, 39-46.
2. Bartus, R.T., Dean, R.L., Beer, B., Lippa, A.S., 1982. The cholinergic hypothesis of geriatric memory dysfunctions. Science 217, 408-417.
3. Blagosklonny, M.V., Neckers, L.M., 1994. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs. Anti-Cancer Drugs 5, 437-442.
4. Bradford, M., 1976. A rapid and sensitive method for the quantification of microgram of protein in utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
5. Brito, G.N., Davis, B.J., Stopp, L.C., Stanto, M.E., 1983. Memory and septo-hippocampal cholinergic system in the rat. Psychopharmacology 81, 315-320.
6. Capaccioli, S., Di Pasquale, G., Mini, E., Mazzei, T., Quattrone, A., 1993. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Comm. 107, 818-825.
7. Caufield, M.P., Higgins, G.A., Straughan, D.W., 1983. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. J. Pharm. Pharmacol. 35, 131-132.
8. Chou, Q., Russell, M., Birch, D.E., Raymond, J., Bloch, W., 1992. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. Nucleic Acids Res. 20, 1717-1723.
9. Cortes, R., Palacios, J.M., 1986. Muscarinic cholinergic receptor subtypes in the rat brain: I quantitative autoradiographic studies. Brain Res. 362, 227-238.
10. Cortes, R., Probst, A., Tobler, H.J., Palacios, J.M., 1986. Muscarinic receptor subtypes in the human brain: II quantitative autoradiographic studies. Brain Res. 362, 239-253.
11. Crooke, S.T., Bennett, C.F., 1996. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 107-129.
12. Duetsch, J.A., 1971. The cholinergic synapse and the site of memory. Science 174, 788-794.
13. 1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci. Lett. 102, 325-331.
14. Galeotti, N., Ghelardini, C., Papucci, L., Quattrone, A., Capaccioli, S., Bartolini, A., 1997. An antisense oligonucleotide to the mouse Shaker-like potassium channel Kv1.1 gene prevents the antinociception induced by morphine and baclofen. J. Pharmacol. Exp. Ther. 281, 941-949.
15. Gao, W.-Y., Han, F.-S., Storm, C., Egan, W., Chen, Y.-C., 1992. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41, 223-229.
16. 1 antagonist in vivo and in vitro. Life Sci. 58, 991-1000.
17. Ghelardini, C., Galeotti, N., Pecori Vettori, A., Capaccioli, S., Quattrone, A., Bartolini, A., 1997. Effect of potassium channels modulation on mouse feeding behaviour. Eur. J. Pharmacol. 329, 1-8.
18. Ghelardini, C., Gualtieri, F., Romanelli, M.N., Angeli, P., Pepeu, G., Giovannini, M.G., Casamenti, F., Malmberg-Aiello, P., Giotti, A., Bartolini, A., 1997. Stereoselective increase in cholinergic transmission by R-(+)-hyoscyamine. Neuropharmacology 36, 281-294.
19. 1 muscarinic selective antagonists trihexyphenidyl and dicyclomine. Br. J. Pharmacol. 89, 83-90.
20. Goodchild, J., 1989. Inhibition of gene expression by oligonucleotides. In: Cohen, J. (Ed.), Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression. Macmillan, London, pp. 53-77.
21. Gualtieri, F., Dei, S., Manetti, D., Romanelli, M.N., Scapecchi, S., Teodori, E., 1995. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. I1 Farmaco 50, 489-503.
22. 1 muscarinic antagonist pirenzepine. Psychopharmacology 93, 470-476.
23. Haley, T.J., McCormick, W.G., 1957. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 12, 12-15.
24. Hammer, R., Berrie, C.P., Birdsall, N.J.M., Burgen, A.S.V., Hulme, E.C., 1980. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283, 90-91.
25. Hunter, A.J., Roberts, F.F., 1988. The effect of pirenzepine on spatial learning in the Morris water maze. Pharmacol. Biochem. Behav. 30, 519-523.
26. Jarvik, M.E., Kopp, R., 1967. An improved one-trial passive avoidance learning situation. Psychol. Rep. 21, 221-224.
27. 2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228, 115-117.
28. 1 antagonist S-(-)-ET-126. 27th Annual Meeting Society for Neuroscience, New Orleans, Louisiana, October 25-30, 23, 213.
29. Meiri, N., Ghelardini, C., Tesco, G., Galeotti, N., Dahl, D., Tomsic, D., Cavallaro, S., Quattrone, A., Capaccioli, S., Bartolini, A., Alkan, D.L., 1997. Antisense inhibition of the rodent Shaker-like potassium channel Kv1.1: disruption of memory without effects on LTP. Proc. Natl. Acad. Sci. USA 94, 4430-4434.
30. Messer W.S., Hoss W.P., Thomas G.J., 1985. Intrahippocampal injections of pirenzepine selectively impair representational memory. 15th Annual Meeting Society for Neuroscience, Dallas, TX, October 20-25, 11, 1294.
31. Munson, P.J., Rodbard, D., 1980. LIGAND: a versatile computerized approach for characterization of ligand-binding system. Anal. Biochem. 107, 220-239.
32. Ng, S.Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Shows, T., Kedes, L., 1985. Evolution of the functional human β-actin gene and its multipseudogene family: conservation of non-coding regions and chromosomal dispersion of pseudogenes. Mol. Cell Biol. 5, 2720-2732.
33. Nilvebrant, L., Sparf, B., 1986. Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites. Eur. J. Pharmacol. 123, 133-143.
34. 2 receptor antagonist AF-DX 116 improves memory. Brain Res. 524, 72-76.
35. Quattrone, A., Fibbi, G., Pucci, M., Anichini, E., Capaccioli, S., Del Rosso, M., 1995. Reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibiting the urokinase receptor gene expression. Cancer Res. 55, 91-95.
36. Quattrone, A., Papucci, L., Morganti, L., Coronnello, M., Mini, E., Mazzei, T., Colonna, F.P., Garbesi, A., Capaccioli, S., 1994. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance in neoplastic cells. Oncol. Res. 6, 311-320.
37. Quattrone, A., Papucci, L., Santini, V., et al., 1995. Quantitation of bcl-2 oncogene expression in cultured follicular lymphoma and primary leukemia B-cells by a highly sensitive RT-PCR method. Haematologica 80, 495-504.
38. Quattrone, A., Papucci, L., Schiavone, N., Mini, E., Capaccioli, S., 1994. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. Anti-Cancer Drug Design 9, 549-553.
39. Sala, M., Braida, D., Calcaterra, P., Leone, M.P., Comotti, F.A., Gianola, S., Gori, E., 1991. Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat. Eur. J. Pharmacol. 194, 45-49.
40. Schick, B.P., Eras, J.L., Mintz, P.L., 1995. Phosphorothioate oligonucleotides cause degradation of secretory but not intracellular serglycin proteoglycan core protein in a sequence-independent manner in human megacaryocytic tumor cells. Antisense Res. Dev. 5, 59-65.
41. Sen, A.P., Bhattacharya, S.K., 1991. Effect of selective muscarinic receptor agonists and antagonists on active-avoidance learning acquisition in rats. Ind. J. Exp. Biol. 29, 136-139.
42. 1 muscarinic acetylcholine receptor gene. J. Biol. Chem. 263, 18397-18403.
43. Singh, H.K., Ott, T., Matthies, H., 1974. Effect of intrahippocampal injection of atropine on different phases of a learning experiment. Psychopharmacologia 38, 247-258.
44. Squire, L.R., Zola, S.M., 1996. Structure and function of declarative and nondeclarative memory systems. Proc. Natl. Acad. Sci. USA 93, 13515-13522.
45. Stein, C.A., Cheng, Y.-C., 1993. Antisense oligonucleotides as therapeutic agents - Is the bullet really magic? Science 261, 1004-1011.
46. Storey, A., Oates, D., Banks, L., Crawford, L., Crook, T., 1991. Antisense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res. 19, 4109-4114.
47. Vaught, J., Pelley, K., Costa, L.G., Sether, P., Enna, S.J., 1985. A comparison of the antinociceptive responses to GABA-receptor agonists THIP and baclofen. Neuropharmacology 24, 211-216.
48. Wahlestedt, C., 1994. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15, 42-46.
49. Whitehouse, P.J., 1986. Neuronal loss and neurotransmitter receptor alterations in Alzheimer's disease. In: Fisher, A., Hanin, I., Lachman, C. (Eds.), Alzheimer's and Parkinson's Diseases: Strategies for Research and Development. Plenum Press, New York, pp. 85-94.
50. Whitesell, L., Geselowitz, D., Chavany, C., Fahmy, B., Walbridge, S., Alger, J., Neckers, L.M., 1993. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. USA 90, 4665-4669.
51. Zang, Z., Florijn, F., Creese, I., 1994. Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochem. Pharmacol. 48, 225-228.
52. Zola-Morgan, S., Squire, L.R., 1993. Neuroanatomy of memory. Annu. Rev. Neurosci. 16, 547-563.